6-Deoxyfagomine | 197449-09-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 6-Deoxyfagomine
• 英文别名: 2-methylpiperidine-3,4-diol
• CAS: 197449-09-5
• 化学式: C₆H₁₃NO₂
• 分子量: 131.17
• InChiKey: RMJCALHKIHCSMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52.5
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• [EN] SYNTHESIS OF DGJNAC FROM D-GLUCURONOLACTONE AND USE TO INHIBIT ALPHA-N-ACETYLGALACTOSAMINIDASES<br/>[FR] SYNTHÈSE DU DGJNAC À PARTIR DU D-GLUCURONOLACTONE, ET SON UTILISATION POUR INHIBER LES ALPHA-N-ACÉTYLGALACTOSAMINIDASES
  申请人：UNIV OXFORD

  公开号：WO2011095893A1

  公开（公告）日：2011-08-11

  A convenient and scalable synthesis of DGJNAc ID from D-glucuronolactone in an overall yield of 20% is provided. DGJNAc is the first highly potent and specific competitive inhibitor of GalNAcases. DGJNAc ID is also a competitive inhibitor of -hexosaminidases. Synthesis and activity of L-DGJNAc IL is also shown. The use of DGJNAc as a potent and specific inhibitor of GalNAcases will allow useful investigation and treatment of a number of diseases, including Schindler Disease.

  提供了一种方便且可扩展的合成方法，从D-葡萄糖醛酸内酯中合成DGJNAc ID，总收率为20%。DGJNAc是第一种高效而特异的竞争性GalNAcases抑制剂。DGJNAc ID也是-hexosaminidases的竞争性抑制剂。还展示了L-DGJNAc IL的合成和活性。将DGJNAc用作GalNAcases的高效而特异的抑制剂，将允许对许多疾病进行有用的研究和治疗，包括Schindler病。
• Extracts of Cranberry and Methods of Using Thereof
  申请人：Alberte Randall S.

  公开号：US20100028469A1

  公开（公告）日：2010-02-04

  The present disclosure relates in part to extracts of cranberry ( Vaccinium macrocarpon ) comprising an enriched amount of certain compounds having anti-infective activity, e.g. antibacterial and/or antifungal activity, e.g. activity against C. albicans . Another aspect of the disclosure relates to combined cranberry and cinnamon extracts. In certain embodiments, these combined extracts have been optimized to control urinary tract infections caused by E. coli, S. aureus and C. albicans . Certain embodiments of the extract are enriched in bioactive compounds that have been shown to inhibit C. albicans adhesion and/or biofilm formation and its growth in vitro. In another aspect of the disclosure, the extracts are enriched in bioactives derived from cranberry and cinnamon that have been shown to inhibit the attachment and the growth of common urinary tract pathogens like E. coli, S. aureus and C. albicans.
• Extracts of Curcuma and Methods of Use Thereof
  申请人：Alberte Randall S.

  公开号：US20100098788A1

  公开（公告）日：2010-04-22

  The present invention relates in part to turmeric extracts that are useful for treating or preventing neurodegenerative disorders. Another aspect of the invention relates in part to turmeric extracts that are useful for treating or preventing inflammatory disorders. In some embodiments, the extracts comprise at least one compound selected from the group consisting of 25 to 500 μg bamosamine, 25 to 750 μg echinaxanthol, 100 to 3,000 μg bisdemethoxycurcumin, 50 to 500 μg daphniyunnine E and 500 to 75,000 μg curcumin per 100 mg of extract. Another aspect of the invention relates to pharmaceutical compositions comprising the aforementioned extracts. Another aspect of the invention relates to methods of treating or preventing neurodegenerative disorders comprising administering to a subject in need thereof an effective amount of the aforementioned extracts or compositions. Another aspect of the invention relates to methods of making the aforementioned extracts.